

Juan P Lopez-Siguero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2051641/publications.pdf>

Version: 2024-02-01

9
papers

91
citations

1684188
5
h-index

1372567
10
g-index

12
all docs

12
docs citations

12
times ranked

161
citing authors

#	ARTICLE	IF	CITATIONS
1	Delphi consensus on the diagnosis and treatment of patients with short stature in Spain: GROW-SENS study. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 887-897.	3.3	0
2	Metabolic Control of the FreeStyle Libre System in the Pediatric Population with Type 1 Diabetes Dependent on Sensor Adherence. <i>Journal of Clinical Medicine</i> , 2022, 11, 286.	2.4	3
3	Factors influencing height gain in children born small for gestational age treated with recombinant growth hormone: what extent is puberty involved?. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2022, 13, 204201882210835.	3.2	5
4	Growth hormone treatment does not lead to insulin resistance nor excessive rise in IGF-1 levels, while improving height in patients small for gestational age A long-term observational study. <i>Clinical Endocrinology</i> , 2022, 96, 558-568.	2.4	4
5	Isolated Growth Hormone Deficiency and Idiopathic Short Stature: Comparative Efficiency after Growth Hormone Treatment up to Adult Height. <i>Journal of Clinical Medicine</i> , 2021, 10, 4988.	2.4	4
6	Predicted Benign and Synonymous Variants in CYP11A1 Cause Primary Adrenal Insufficiency Through Missplicing. <i>Journal of the Endocrine Society</i> , 2019, 3, 201-221.	0.2	27
7	Ten years experience with the first approved biosimilar recombinant human growth hormone drug in normal clinical practice. <i>Anales De Pediatr�a (English Edition)</i> , 2018, 88, 209-215.	0.2	1
8	Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 1489-1495.	4.3	12
9	A Follow-up Study to Monitor Adult Height Among Spanish Children with Growth Hormone Deficiency Who Received Biosimilar Human Recombinant Growth Hormone (Omnitrope�) During a Phase III Clinical Trial. <i>Advances in Therapy</i> , 2015, 32, 148-156.	2.9	9